Hollis-Eden touts new diabetes data; Nastech announces positive insulin report

> Hollis-Eden says new data from a Phase I/II trial of triolex for type 2 diabetes continues to show the drug is safe and well tolerated while also demonstrating that it significantly improves insulin sensitivity and improved other key targets. Report

> Nastech Pharmaceutical announced positive Phase II data demonstrating that its intranasal insulin was both superior to usual therapy and non-inferior to insulin aspart, a rapid-acting injectable insulin, in maintaining glucose control at both 60 and 90 minutes following a meal. Release

> The UK's Bioniq has won a 50,000 euro investment to advance its work on an anti-malaria drug. Report

> It's been rumored for weeks, and now Sanofi-Aventis is confirming. Yes, the French drugmaker will cut jobs at home in France. Details are sketchy, but here's what we know: Sanofi will lay off 700 to 800 sales reps. Layoff report

> Think the FDA has been falling all over itself to issue warning letters lately? Think again. A look at agency statistics showed that the number of warning letters actually dropped by half--yes, half--in the last 10 years. FDA report

> There's been a lot of talk lately about whether a "by the numbers" approach to disease is really effective. Report

> Curious about the man Jeff Kindler brought in to strategize about Pfizer's finances? The Star-Ledger pulls back the curtain on CFO Frank D'Amelio (photo), the ex-Lucent exec who's charged with executing an equally dramatic makeover at Pfizer. Report

And Finally... Duke engineers say that a genetic tool used by medical researchers may also be used in a novel approach to remove harmful microbes and viruses from drinking water. Release

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.